CHMP confirms negative opinion on Amylyx's AMX0035 for ALS in EU

Amylyx Pharmaceuticals, Inc.

CHMP confirmed its initial negative opinion on Marketing Authorisation Application for AMX0035 (ALBRIOZA) for ALS.
Formal re-examination procedure concluded, upholding June 2023 initial negative opinion.
Decision applies to European Union marketing authorization for AMX0035.

item 8.01

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-256178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.